Page 33 - Gates-AnnualReport-2018

Gates Center Entrepreneur in Residence Heather Callahan and 2017 Awardee Valeria Canto-Soler
2017 Awardee Karin Payne and collaborator Nancy Miller, M.D.
Gates Grubstake Fund investment decisions are made on a competitive basis by members of the Scientific Investment Advisory Committee (SIAC):
• Mark Brunvand, M.D., former Director of Unrelated Donor Transplantation, Colorado Blood Cancer Institute; Medical Director for Transplantation, Cigna
• William Hiatt, M.D., Professor, Division of Cardiology, University of Colorado Anschutz Medical Campus; President, CPC Clinical Research; member, Gates Center Advisory Board
• Ryan Kirkpatrick, Partner, Colorado Impact Fund
• David L. Lacey M.D., Biopharmaceutical Consultant, former SVP, head of research, Amgen
• Mark Lupa, Ph.D., Principal, High Country Ventures
• Kimberly Muller, J.D., Managing Director, CU Innovations, University of Colorado Anschutz Medical Campus
• Michael Perry, DVM, Ph.D., FACVPT, Chief Executive Officer, Avita Medical Ltd.; Managing Director, Bioscience
Managers Pty Ltd
• J. Mark Petrash, Ph.D., Professor and Vice Chair, Department of Ophthalmology, Associate Director, Gates Center for
Regenerative Medicine, University of Colorado Anschutz Medical Campus
• Geoff “Duffy” Solich, Executive Vice President, E & P Resources LLC; member, Gates Center Advisory Board
• Ann Sperling, Senior Director, Trammell Crow Company; member, Gates Center Advisory Board
• Robert Traver, J.D., Patent Attorney, Sheridan Ross
Gates Center for Regenerative Medicine 33